The US Food and Drug Administration (FDA) has granted approval to Lupin Pharmaceuticals to market a generic version of CP Pharmaceuticals' Lyrica (Pregabalin) capsules.
Lupin's generic equivalent of Lyrica capsules are manufactured as Pregabalin Capsules with dosage forms of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.
Lyrica capsules are indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and post herpetic neuralgia.
Lyrica capsules are also indicated for use during adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-approves-lupin-generic-lyrica-capsules-060712
